• Cardiovascular event risk reduction in Type 2 DM in patients with established CV disease
  • Kidney disease progression and CV-related risk reduction in Type 2 DM with nephropathy and albuminuria >300 mg/day
  • Type 2 DM

Dose: 100mg OD before 1st meal of the day.

  • May increase to 300mg/day in eGFR ≥60 mL/min/1.73 m²

Tablet:

  • 100mg
  • 300mg

To be taken before the first meal of the day

Selective sodium-glucose transporter-2 (SGLT2) inhibitor

Inhibition of sodium-glucose cotransporter-2  lowers the renal glucose threshold reducing glucose/sodium reabsorption, increasing urinary glucose excretion and sodium delivery to distal tubule

  • Hyperkalemia
  • Genital mycotic infection
  • Increased cholesterol
  • Increased magnesium
  • Hypoglycemia
  • UTI
  • Increased urination
  • Increased phosphate
  • Increased Hb
  • Vulvovaginal pruritus
  • Thirst
  • Orthostatic hypotension
  • Constipation
  • Nausea
  • Fatigue
  • Increased Cr
  • Lower limb amputation risk
  • Hypersensitivity to drug/compound
  • Pregnancy 2nd or 3rd trimester
  • Type 1 DM
  • Diabetic ketoacidosis
  • Volume depletion
  • eGFR <30

None restricted

                          Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Invokana 100mg Tablet 30’s Janssen-Cilag Phillips Therapeutics
Invokana 300mg Tablet 30’s Janssen-Cilag Phillips Therapeutics